Journals / Türk Pediatri Arşivi / 2018 / Cilt: 53 - Sayı: 2

A rare cause of sudden cardiac arrest: Catecholaminergic polymorphic ventricular tachycardia

Ani kalp durmasının nadir bir nedeni: Katekolaminerjik polimorfik ventriküler taşikardi

Pages
124–128
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case is presented with the purpose of highlighting catecholaminergic polymorphic ventricular tachycardia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Catecholaminergic polymorphic ventricular tachycardia is a rhythm disorder that develops due to genetic reasons in the absence of structural cardiac abnormalities.
📊
Key Findings & Data:A genetic test revealed heterozygote missense mutation (c.9110G>A(p.Gly3037Asp)) in exon 64 of the RYR2 gene, which is compatible with catecholaminergic polymorphic ventricular tachycardia.
💡
Conclusion & Impact:This case is presented with the purpose of highlighting catecholaminergic polymorphic ventricular tachycardia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Catecholaminergic polymorphic ventricular tachycardia is a rhythm disorder that develops due to genetic reasons in the absence of structural cardiac abnormalities. Ventricular tachycardia, ventricular fibrillation, cardiac arrest, and death may occur. Two-year-old patient presented to the Emergency Department with sudden cardiac arrest. He had syncope attacks after playing with his brother and he was followed up by the pediatric neurology and cardiology clinics. Cardiopulmonary resuscitation was performed, and he was then transferred to the Intensive Care Unit because of hypotension; dobutamine and norepinephrine treatment was started. After treatment, ventricular tachycardia, ventricular fibrillation, and cardiac arrest developed. Dobutamine and noradrenaline was stopped immediately and amiodarone was started. A genetic test revealed heterozygote missense mutation (c.9110G>A(p.Gly3037Asp)) in exon 64 of the RYR2 gene, which is compatible with catecholaminergic polymorphic ventricular tachycardia. This mutation has been reported in the literature for the first time. This case is presented with the purpose of highlighting catecholaminergic polymorphic ventricular tachycardia.

Özet

Katekolaminerjik polimorfik ventriküler taşikardi yapısal kalp hastalığı olmaksızın, genetik nedenlere bağlı olarak gelişen bir ritimbozukluğudur. Efor ve duygusal stres gibi sempatik uyarıyı arttırannedenlerle tetiklenen ventriküler taşikardi, ventriküler fibrilasyon,ani kalp durması ve ölüm gelişebilir. İki yaşındaki olgu Acil Servis’eani kalp durması tablosunda getirildi. Öyküsünden ağabeyi ile oynadıktan sonra bayılmaları olduğu, bu nedenle başka bir merkezinçocuk nöroloji ve çocuk kardiyoloji polikliniklerinden izlendiği öğrenildi. Kalp ve akciğer canlandırması uygulanarak entübe edildive Yoğun Bakım Birimi’ne yatırıldı. Kan basıncı düşük seyrettiğiiçin dobutamin ve noradrenalin başlandı. Tedavinin başlanması ileventriküler taşikardi ve ventriküler fibrilasyon ve ani kalp durmasıoldu. Dobutamin ve noradrenalin kesildi, amiodaron başlandı. Olgumuzun genetik çalışmasında katekolaminerjik polimorfik ventriküler taşikardi ile uyumlu olarak RyR2 geni ekzon 64’te heterozigotc.9110G>A(p.Gly3037Asp) yanlış anlamlı mutasyonu saptandı. Bumutasyon dizinde ilk kez bildirilmektedir. Bu olgu efor ile bayılanhastalarda, nadir görülen katekoliminerjik polimorfik ventrikülertaşikardiye dikkat çekmek ve ilk kez tanımlanan gen mutasyonunubildirmek amacı ile sunulmuştur.

🔖

Cite This Article

Koka, A., Atik, S. U., Öztunç, F., Dedeoğlu, R., Eroğlu, A. G., Alp, F. E. (2022). A rare cause of sudden cardiac arrest: Catecholaminergic polymorphic ventricular tachycardia. Türk Pediatri Arşivi, Cilt: 53 - Sayı: 2, 124–128. https://ajindex.com/articles/641053

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Spears DA, Gollob MH. Genetics of inherited primary arrhythmia disorders. Appl Clin Genet 2015; 8: 215-33
  2. Kron J, Ellebogen K, Abbate A. Recurrent ventricular fibrillation in a young female carrying a previously unidentified RyR2 gene mutation. Int J Cardiol 2015; 201: 222-4. [CrossRef] 3. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 675-8. [CrossRef ] 4. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378-84. [CrossRef ] 5. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74. [CrossRef ] 6. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292: 1341-4. [CrossRef ] 7. Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2016; 13: 433-40. [CrossRef ] 8. Sioros L, Baltogiannis GG, Lysitsas DN, Kolettis TM. Treatment of catecholaminergic polymorphic ventricular tachycardia: lessons from one case. Hosp Chron 2014, 9: 27-32
  3. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation 2015; 131: 2185-93. [CrossRef ] 10. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013; 10: 1932-63. [CrossRef ]